Webinars

The session will focus on a new study appearing in the April 2022 issue of Health Affairs, “Health-Related Social Needs Among Older Adults Enrolled In Medicare Advantage (MA).” Authors Brian W. Powers and Stephanie M. Franklin, both of Humana, will present the findings of a large, national survey of older adults enrolled in MA, which found a high burden of health-related social needs, including financial strain, food insecurity, and poor housing quality, as well as significant disparities according to race, socioeconomic status, and sex. They will be joined by Monica E. Peek of the University of Chicago, a frequent Health Affairs contributor, whose work – including the 2021 Forefront article, “As They Take On Food Insecurity, Community-Based Health Care Organizations Have Found Four Strategies That Work” -- explores many of the same issues.

When it comes to providing meaningful support to consumers, patient services are on the front line. Recent data shows that patients’ interest in support services has reached an unprecedented high since the pandemic, but wavering trust in pharma companies is creating a barrier to service utilization and adherence. To build trust, pharmaceutical companies need to improve patient satisfaction through more expansive service, streamlined support, and closer collaboration with healthcare providers. In this webinar, Salesforce speaks with experts from Novartis, ViiV Healthcare, Curémonos and Biogen to explore how pharma companies can improve trust to drive better patient services engagement and adherence.

Digital health has transformed many parts of the healthcare industry and improved upon the patient experience. But is there room in digital health for caregivers? How are new technology advancements helping to support the role of caregivers in the patient journey? And what are the unique challenges that caregivers face that may be different from the patient themselves? This roundtable discussion unites digital health leader, caregivers, and patients to explore the role of caregivers and how digital health is changing how to juggle the demands of caring for another, and the advancements needed for caregivers. Panelists will share their recommendations on how to reach caregivers and what digital elements could help to improve the role of caregivers.

Each year, universities and research institutions across the country compete in STAT’s bracket-style tournament, STAT Madness, to be crowned the top biomedical innovation or discovery of the year. Over five weeks, STAT readers voted for their favorites until a winner was selected from the initial field of 64 entries. Hear a researcher from the winning team discuss their work, its potential impact, and what’s next in their field.

Longstanding healthcare industry inefficiencies lead to affordability, outcome, quality challenges, and poor consumer experiences. The healthcare industry has been among the last to adopt experiential digitization that consumers have become accustomed to in other areas of their life. Meanwhile, healthcare regulatory changes call for health data interoperability and greater price transparency for consumers. These imperatives will require healthcare stakeholders to collaborate much more closely for the benefit of the patient. With our panel of experts and leaders across healthcare, biopharma, and high tech, we will explore these industry dynamics and discuss how this dynamic will change the rules of engagement within the industry. We will discuss the role technology can play in bringing stakeholders together, and in turn, explore and define any obvious areas where collaboration is a win-win opportunity and be open about where challenges will continue to arise.

In this episode, Flatiron leaders and key clinical research partners will share our vision for the future of oncology clinical research and showcase case studies of early successes, particularly around the use of technology to streamline study data capture (EHR to EDC).

The demand for plasmid DNA, a critical component to many biological therapeutics, has grown concurrently with advances and successes in cell, gene and mRNA therapies. A plasmid DNA manufacturing platform can support early activities and facilitate the transition towards GMP production for clinical and commercial supply. Securing the supply of this critical raw material will help biotech and pharma companies throughout the drug development lifecycle of their advanced therapies. Join the webinar to learn:The features of a plasmid manufacturing platform process, how starting at the lead identification and tox phases support and expedite the transition towards GMP manufacturing, and the advantages of securing plasmid bioproduction services that are fully integrated within viral vector and cell therapy manufacturing capabilities.

This session educates about the specific challenges of rare disease treatments in an HTA and discusses how Real-World Evidence Collection can address the data gap at the time of access decision. The three expert speakers will discuss the opportunities, challenges and limitations of Real-World Evidence Collection based on their practical experience in the rare disease area of Spinal Muscular Atrophy (SMA), a severe neuromuscular genetic disorder. In this interactive and moderated session you will hear their ideas how to promote a better coordination in Real-World Evidence Collection and listen to their suggestions how to facilitate its acceptance by Patients, Physicians and Payers.  

HealthVerity is pleased to introduce significant new additions to lab data, medical claims data, in-patient data and mortality data to the nation's largest ecosystem for healthcare and consumer data. We believe that this new wave of data partners will generate powerful new insights for our Pharmaceutical, Insurance and Government clients across a wide range of research and analytics applications. Join us on Thursday, March 31 at 12PM EDT for an overview of the newest additions to the HealthVerity RWD ecosystem and to learn more about the top use cases for these invaluable sources.

Join Sanofi, Novartis, Novo Nordisk, Sitecore and FCB Health as they explore how to unify sources through a 1st party data platform, optimise customer profiles and build a deeper understanding of HCP preferences to enable hyper-segmentation, automation, and real-time targeting:

On Monday, February 28, 2021, you are invited to join Health Affairs Editor-in-Chief Alan Weil for the next installment of our Policy Spotlight series, featuring Meena Seshamani, Deputy Administrator & Director, Center for Medicare, Centers for Medicare & Medicaid Services (CMS), US Department of Health and Human Services, where she leads the Agency’s efforts to provide affordable, quality coverage and care for more than 63 million Americans that rely on the Medicare program.

This online event will discuss the needs of such special patients, how researchers can address recruitment and enrollment, technologies available to help overcome the challenges such patients present, and more.

This is a virtual event, accessible online and over the phone. Access instructions will be provided after registration.

Medicaid is the single largest source of health coverage in the U.S. Now more than ever before, states are relying heavily on managed care organizations to serve their Medicaid beneficiaries to improve the quality of care delivered and control costs. Managed care plays a key role in the delivery of health care to Medicaid enrollees. With 69% of Medicaid beneficiaries enrolled in comprehensive managed care plans nationally, Medicaid leaders, health plans and managed care organizations play a critical role in responding to the COVID-19 pandemic and in the fiscal implications for states.

Exacerbated by the pandemic, Mental Health disorder prevalence continues to rise. The growing unmet need is driving a renewed interest in research and development programs. Yet, the complexities of these neurological conditions continue to present challenges.

As we emerge from another surge in coronavirus cases, there is good reason to believe we are starting 2022 in a better position than we were this time last year. Yet uncertainty remains. COVID-19 will have a lasting effect on healthcare budgets, as well as in areas such as clinical trials, regulatory processes and reimbursement timelines.

The Medical Device Innovation Consortium’s AI/ML working group have drafted for public comment a framework document that will include the Glossary, SPS template, and ACP template, as well as additional background and context. An informational webinar on the framework and how to submit public comment will be held on Tuesday, February 1, 2022.

In this report, we quantify the impact of these dynamics and examine the spending and usage of medicines in 2021 and the outlook to 2026, globally and for specific therapy areas and countries. We intend this report to provide a foundation for meaningful discussion about the value, cost and role of medicines over the next five years in the context of overall healthcare spending.

Following a forest fire, the natural world recovers according to predictable patterns, in a process known as ‘ecological succession’. After the global conflagration of COVID-19, what will the equivalent patterns look like for health?

Every year we ask our proprietary panel of physicians to share their perspectives on the healthcare industry for the coming year. Amid continued pandemic-related disruption, this year’s global insights will share provider views on the last year, thoughts on coming change in the industry, and their hopes for 2022.

On July 19, 2021, the Centers for Medicare and Medicaid Services (CMS), as part of proposed rule covering a variety of subjects, including Medicare Hospital Outpatient and Ambulatory Surgery Center PPS modifications, issued a proposed rule with an opportunity to comment (the Rule) amending the hospital price transparency regulations. (The Rule is scheduled to be published in the Federal Register on August 4, 2021.) The Rule seeks to modify the existing hospital price transparency regulations codified at 45 C.F.R. part 180 Subpart C. View what may be considered the finest Contract Negotiation & Pricing Transparency Module (Patient Quote) available for Increased Productivity & Reimbursement for Hospitals & Physician Groups

While the FDA has set guidelines on proactive manufacturer communications of healthcare economic information (HCEI) to payers, there still appears to be a gap between what payers are asking for and what manufacturers are providing. So why the gap, and how might this be impacting payer decision making? And what might prove helpful for manufacturers to enhance this exchange? Join our panel for research findings and insights into these critical questions, along with strategies to close the gap.

Join us for a moderated panel discussion with IQVIA leaders following the release of a recent IQVIA Institute report on The Global Use of Medicines 2022.